Comparative Efficacy of Ovule vs Tablet
An Investigator-blinded, Active-controlled Phase 3 Study to Prove the Non-inferior Efficacy of a Clotrimazole Ovule (500 mg) Versus a Clotrimazole Vaginal Tablet (500 mg) in Vaginal Candidiasis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Hamburg, Germany, 22359
-
Hamburg, Germany, 22159
-
-
Baden-Württemberg
-
Freiburg, Baden-Württemberg, Germany, 79106
-
-
Bayern
-
München, Bayern, Germany, 80333
-
München, Bayern, Germany, 85356
-
-
Hessen
-
Frankfurt, Hessen, Germany, 65929
-
Fulda, Hessen, Germany, 36037
-
Wiesbaden, Hessen, Germany, 65197
-
-
Niedersachsen
-
Hannover, Niedersachsen, Germany, 30459
-
Osnabrück, Niedersachsen, Germany, 49074
-
-
Nordrhein-Westfalen
-
Dortmund, Nordrhein-Westfalen, Germany, 44319
-
Krefeld, Nordrhein-Westfalen, Germany, 47799
-
-
-
-
-
Moscow, Russian Federation, 119049
-
Moscow, Russian Federation, 119002
-
Moscow, Russian Federation, 129090
-
Moscow, Russian Federation, 127473
-
Moscow, Russian Federation, 117198
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-pregnant females aged at least 14 years in Germany or at least 16 years in Russia and not older than 50 years.
- Subjects presenting a symptomatic vulvovaginal yeast infection confirmed by microscopic evaluation (wet mount preparation).
- Subjects must be cooperative, able to understand the requirements of the trial participation, and willing to participate in the trial. For adolescents the informed consent has to be provided to a legal representative in addition.
- Subjects of childbearing potential must use an acceptable method of contraception. Hormonal or oral contraceptive drugs, intra-uterine devices (IUD) and abstinence are considered acceptable methods of contraception.
- Negative saline smear for Trichomonas vaginalis
Exclusion Criteria:
- Subjects with known hypersensitivity to imidazoles or triazoles and their analogues.
- Subjects presenting a protozoan infection as confirmed by microscopic investigation.
- Pregnant, breast feeding or lactating subjects.
- Subjects with suspected bacterial vaginal infection.
- Subjects with abdominal pain, fever, or foul smelling vaginal discharge.
- Subjects who had a vaginal infection, or who had used an intravaginal or systemic antimycotic treatment within 60 days prior to visit 1.
- Subjects using or wishing to use intra-vaginal or systemic anti-infectives or systemic antifungal therapy during the trial.
- Subjects wishing to use contraceptive foams, creams, jellies, sponges, therapeutic ointments, condoms, diaphragms, and OTC vaginal products during treatment and 3 days thereafter (i.e. until day 4).
- Subjects unable to refrain from the use of vaginal tampons during treatment and for 3 days thereafter (i.e. until day 4).
- Subjects unable to refrain from the use of feminine hygiene products (e.g. douches, feminine deodorant products) for 2 weeks (i.e. from visit 1 until visit 2).
- Subjects suffering from chronic/recurrent vulvovaginal mycosis, defined as 4 or more mycologically proven symptomatic episodes during the last 12 months.
- Subjects suffering from diseases (e.g. diabetes, decreased cellular immunity) or being treated with drugs (e.g. immunosuppressants, corticosteroids, anti-infectives) which may predispose them to mycological infections.
- Subjects who received another investigational drug within 30 days before visit 1.
- Unwillingness to refrain from sexual activity during 3 days thereafter.
- Actual menstruation at visit 1 or expected menstruation within 4 days after visit 1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Clotrimazole tablet (Canesten, BAY-B5097)
Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
|
Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
|
|
Experimental: Clotrimazole ovule (Canesten, BAY-B5097)
Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
|
Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Subjects With Overall Response at Visit 2 (Day 10 to 14)
Time Frame: 10-14 days after treatment (=visit 2)
|
10-14 days after treatment (=visit 2)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Subjects With Overall Response at Visit 3 (Week 6 to 8)
Time Frame: 6-8 weeks after treatment (=visit 3)
|
6-8 weeks after treatment (=visit 3)
|
|
Percentage of Subjects With Clinical Cure at Visit 2 (Day 10 to 14)
Time Frame: 10-14 days after treatment (=visit 2)
|
10-14 days after treatment (=visit 2)
|
|
Percentage of Subjects With Clinical Cure at Visit 3 (Week 6 to 8)
Time Frame: 6-8 weeks after treatment (=visit 3)
|
6-8 weeks after treatment (=visit 3)
|
|
Percentage of Subjects With Mycological Cure at Visit 2 (Day 10 to 14)
Time Frame: 10-14 days after treatment (=visit 2)
|
10-14 days after treatment (=visit 2)
|
|
Percentage of Subjects With Mycological Cure at Visit 3 (Week 6 to 8)
Time Frame: 6-8 weeks after treatment (=visit 3)
|
6-8 weeks after treatment (=visit 3)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections and Mycoses
- Mycoses
- Vaginal Diseases
- Vulvar Diseases
- Vaginitis
- Vulvitis
- Vulvovaginitis
- Candidiasis
- Candidiasis, Vulvovaginal
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Clotrimazole
- Miconazole
Other Study ID Numbers
Other Study ID Numbers
- 13071
- 2008-000718-63 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.